You are here: Home » Companies ¬Ľ News
Air India leases 12 more aircraft to enhance international operations
icon-arrow-left
Business Standard

Price war begins for Novartis cardiac drug as JB Pharma cuts rate by 50%

Novartis' blockbuster drug is set to lose patent in Jan; JB Pharma, one of the four marketers in India of generi versions, has slashed the price of its brand Azmarda to Rs 39.6 a tablet

Topics
Novartis India | Medicines | health care

Sohini Das  |  Mumbai 



pharmacy, drugs, medicine, pharma companies, pharmaceuticals
At present, Azmarda is the third largest brand in the category, and commanded 17 per cent market share with moving annual turnover (MAT) sales of Rs 93.5 crore in October

JB Pharma on Monday likely kicked off a price war after it cut by half the price of Azmarda, a cardiac drug patented by Novartis.

TO READ THE FULL STORY, SUBSCRIBE NOW NOW AT JUST RS 249 A MONTH.

SUBSCRIBE TO INSIGHTS

What you get on Business Standard Premium?

  • icon Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • icon Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • icon Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
  • icon Pick your 5 favourite companies, get a daily email with all news updates on them.
  • icon 26 years of website archives.
  • icon Preferential invites to Business Standard events.

OR


Subscribe to Business Standard Premium

Exclusive Stories, Curated Newsletters, 26 years of Archives, E-paper, and more!

Insightful news, sharp views, newsletters, e-paper, and more! Unlock incisive commentary only on Business Standard.

Download the Business Standard App for latest Business News and Market News .

First Published: Mon, December 05 2022. 14:37 IST

RECOMMENDED FOR YOU

.